Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with locally advanced or metastatic solid tumors who have received three or less prior lines of systemic chemotherapy~* Participants must have relapsed or had progressive disease following standard of care treatment with chemotherapy prior to enrollment, or intolerant to prior standard of care treatment with chemotherapy~* Normal cardiac conduction and function as documented on a 12-lead electrocardiogram~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1~* Adequate organ function as evidenced by laboratory tests~* Able to receive dexamethasone or its equivalent~* Agrees to protocol-defined use of effective contraception~Exclusion Criteria:~* Participants treated with more than three prior chemotherapy regimens (including adjuvant therapy)~* Previous exposure to trabectedin~* Central nervous system (CNS) metastasis~* Known hypersensitivity to any of the components of the trabectedin intravenous formulation or dexamethasone~* Heart rhythm disturbances, unusual T wave and U wave (if present) morphology, blood pressure outside of normal range, a history of cardiac failure, myocardial infarction, or cardiomyopathy, or a history of additional risk factors for torsade de pointes (eg, heart failure, electrolyte abnormalities, family history of Long QT Syndrome)~* Participants who at screening are on medication that is known to prolong the QT interval or who is on CYP3A4 inhibitors or inducers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Trabectedin (Type: EXPERIMENTAL): 3-hour placebo intravenous infusion on Day 1 and trabectedin 1.3 mg/m2 3-hour intravenous infusion on Day 2 (single-blind). Patients may continue treatment with trabectedin until clinical benefit or drug is commercially available (open-label).

Based on this trial design, predict the completion outcome and termination type (if applicable).